The Swiss major's biggest seller rose 12% in the second quarter and while COVID-19 had an impact, and competition is on the rise, Cosentyx is still outpacing the market overall in psoriasis, while rheumatology should drive future growth.

Manufacturers developing devices to remove tissue in the prostate should provide the US FDA with follow-up information on patients that include certain indirect data about the long-term safety outcomes of using their product, according to a final agency guidance.

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.

Partnership will combine AbCellera’s screening of antibodies to the virus with Lilly’s development, commercial capabilities. Vir adds Biogen tie-up to its ongoing coronavirus efforts.